Allergan tries to escape Restasis IPRs
brianajackson / iStockphoto.com
The US Court of Appeals for the Federal Circuit has ordered the Patent and Trial Appeal Board (PTAB) to halt its review of patents covering a dry eye medication while the court considers arguments that tribal immunity protects the patents from board proceedings.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Patent and Trial Appeal Board, Allergan, Restasis inter partes review, Saint Regis Mohawk Tribe immunity